Yamada-Hunter, Sean A. http://orcid.org/0000-0002-4372-6587
Theruvath, Johanna
McIntosh, Brianna J. http://orcid.org/0000-0003-3626-625X
Freitas, Katherine A.
Lin, Frank http://orcid.org/0009-0006-2967-9899
Radosevich, Molly T.
Leruste, Amaury http://orcid.org/0000-0002-6891-9588
Dhingra, Shaurya
Martinez-Velez, Naiara
Xu, Peng
Huang, Jing
Delaidelli, Alberto
Desai, Moksha H.
Good, Zinaida http://orcid.org/0000-0003-2343-5771
Polak, Roel http://orcid.org/0000-0001-7815-1202
May, Audre
Labanieh, Louai
Bjelajac, Jeremy
Murty, Tara
Ehlinger, Zach
Mount, Christopher W.
Chen, Yiyun
Heitzeneder, Sabine
Marjon, Kristopher D.
Banuelos, Allison
Khan, Omair
Wasserman, Savannah L.
Spiegel, Jay Y.
Fernandez-Pol, Sebastian
Kuo, Calvin J. http://orcid.org/0000-0002-7427-5985
Sorensen, Poul H.
Monje, Michelle http://orcid.org/0000-0002-3547-237X
Majzner, Robbie G. http://orcid.org/0000-0001-6969-8011
Weissman, Irving L. http://orcid.org/0000-0002-9077-7467
Sahaf, Bita
Sotillo, Elena http://orcid.org/0000-0002-3993-1932
Cochran, Jennifer R. http://orcid.org/0000-0002-6532-9873
Mackall, Crystal L. http://orcid.org/0000-0001-6323-4304
Article History
Received: 8 May 2023
Accepted: 18 April 2024
First Online: 15 May 2024
Competing interests
: S.A.Y.-H., J.T., B.J.M., J.R.C. and C.L.M. are listed as coinventors on a patent related to this work (PCT/US2024/013209, submitted by the board of trustees of the Leland Stanford Junior University). C.L.M. holds equity in CARGO Therapeutics, Link Cell Therapies and Ensoma, which are developing CAR-based therapies; consults for CARGO, Link, Immatics, Ensoma and Red Tree Capital; and receives research funding from Lyell Immunopharma and Tune Therapeutics. S.A.Y.-H. is a consultant for Quince Therapeutics. J.T. is a consultant for Dorian Therapeutics. L.L. and E.S. are consultants for and hold equity in Lyell Immunopharma. L.L. is a cofounder of, consults for and holds equity in CARGO Therapeutics. O.K. is a senior fellow with ARTIS Ventures. C.J.K. is founder and scientific advisory board member for NextVivo, Surrozen and Mozart Therapeutics. R.G.M. is a co-founder of and holds equity in Link Cell Therapies; and is a consultant for NKarta, Arovella Pharmaceuticals, Innervate Radiopharmaceuticals, GammaDelta Therapeutics, Aptorum Group, Zai Labs, Immunai, Gadeta, FATE Therapeutics (DSMB) and Waypoint Bio. I.L.W. is a director, stockholder in and consultant for Forty Seven (but not Gilead); a co-founder of and director and consultant for Bitterroot Bio and PHeast, and a co-founder of 48. I.L.W. is also on the scientific advisory board of Appia. E.S consults for Lepton Pharmaceuticals and Galaria. J.R.C. is a cofounder and equity holder of Trapeze Therapeutics, Combangio and Virsti Therapeutics; has financial interests in Aravive, Xyence Therapeutics and CARGO Therapeutics; and is a member of the board of directors of Ligand Pharmaceuticals and Revel Pharmaceuticals. The other authors declare no competing interests.